Metastatic Prostate Cancer Patients in UK Can Now Have Routine Radium-223 Therapy

Metastatic Prostate Cancer Patients in UK Can Now Have Routine Radium-223 Therapy
The U.K.’s National Institute for Clinical Excellence (NICE) has approved radium-223 to treat prostate cancer that has spread to the bones for routine National Health Service (NHS) use. The approval comes in the wake of new information about how the effectiveness of radium-223 internal radiation therapy compares with treatments currently available for this type of prostate cancer, according to

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *